The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

The Diagnosis of Nonalcoholic Fatty Liver Disease

비알코올 지방간 질환의 진단

  • Kim, Moon Young (Department of Internal Medicine, Yonsei University Wonju College of Medicine)
  • 김문영 (연세대학교 원주의과대학 내과학교실)
  • Published : 2014.04.01
⟨ Previous Next ⟩

Abstract

Nonalcoholic fatty liver disease (NAFLD) is composed of nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH) and NASH related cirrhosis and these are defined by histological findings. These diseases have absolutely typical and different clinical findings and natural courses respectively. NAFL generally has benign process however; NASH and NASH related cirrhosis have an increased risk for liver-related morbidity and mortality. So, the accurate diagnosis and differentiation of steatohepatitis or advanced fibrosis are essential in the management of patient and the prediction of prognosis. The gold-standard of diagnosis of NAFLD is liver biopsy however; it has some limitations in clinical practice. So many studies have been done to find out noninvasive diagnostic methods. These methods can be divided into 2 groups: those that predict the presence of NASH and that predict the presence of advanced fibrosis. This paper provides an overview of various noninvasive methods for detecting NAFLD and their clinical meanings in clinical practice.

Keywords

References

  1. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005;143:722-728. https://doi.org/10.7326/0003-4819-143-10-200511150-00009
  2. Suzuki A, Angulo P, Lymp J, et al. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology 2005;41:64-71. https://doi.org/10.1002/hep.20543
  3. Lee JY, Kim KM, Lee SG, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol 2007;47:239-244. https://doi.org/10.1016/j.jhep.2007.02.007
  4. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140:124-131. https://doi.org/10.1053/j.gastro.2010.09.038
  5. Speliotes EK, Massaro JM, Hoffmann U, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010;51:1979-1987. https://doi.org/10.1002/hep.23593
  6. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013;57:1357-1365. https://doi.org/10.1002/hep.26156
  7. Park SH, Jeon WK, Kim SH, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006;21(1 Pt 1):138-143. https://doi.org/10.1111/j.1440-1746.2005.04086.x
  8. Bae JC, Cho YK, Lee WY, et al. Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. Am J Gastroenterol 2010;105:2389-2395. https://doi.org/10.1038/ajg.2010.275
  9. Choi SY, Kim D, Kim HJ, et al. The relation between nonalcoholic fatty liver disease and the risk of coronary heart disease in Koreans. Am J Gastroenterol 2009;104:1953-1960. https://doi.org/10.1038/ajg.2009.238
  10. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-121. https://doi.org/10.1053/j.gastro.2005.04.014
  11. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419. https://doi.org/10.1016/S0016-5085(99)70506-8
  12. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-873. https://doi.org/10.1002/hep.21327
  13. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011;43:617-649. https://doi.org/10.3109/07853890.2010.518623
  14. Ratziu V, Poynard T. NASH: a hidden and silent fibroser finally revealed? J Hepatol 2005;42:12-14.
  15. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD; American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009;49:1017-1044. https://doi.org/10.1002/hep.22742
  16. Poynard T, Munteanu M, Imbert-Bismut F, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004;50:1344-1355. https://doi.org/10.1373/clinchem.2004.032227
  17. Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011;54:344-353. https://doi.org/10.1002/hep.24376
  18. Loria P, Adinolfi LE, Bellentani S, et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease: a decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis 2010;42:272-282. https://doi.org/10.1016/j.dld.2010.01.021
  19. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-2023. https://doi.org/10.1002/hep.25762
  20. Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:325-348. https://doi.org/10.3350/cmh.2013.19.4.325
  21. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53:372-384. https://doi.org/10.1016/j.jhep.2010.04.008
  22. Kim CW, Chang Y, Sung E, Shin H, Ryu S. Serum ferritin levels predict incident non-alcoholic fatty liver disease in healthy Korean men. Metabolism 2012;61:1182-1188. https://doi.org/10.1016/j.metabol.2012.01.007
  23. Lee YJ, Lee HR, Lee JH, Shin YH, Shim JY. Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults. Clin Chem Lab Med 2010;48:175-180.
  24. Ryoo JH, Choi JM, Moon SY, et al. The clinical availability of non alcoholic fatty liver disease as an early predictor of the metabolic syndrome in Korean men: 5-year's prospective cohort study. Atherosclerosis 2013;227:398-403. https://doi.org/10.1016/j.atherosclerosis.2013.01.002
  25. Choi JH, Rhee EJ, Bae JC, et al. Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: a 4-year longitudinal study. Arch Med Res 2013;44:115-120. https://doi.org/10.1016/j.arcmed.2013.01.007
  26. Kim D, Choi SY, Park EH, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 2012;56:605-613. https://doi.org/10.1002/hep.25593
  27. Alkhouri N, Carter-Kent C, Feldstein AE. Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Rev Gastroenterol Hepatol 2011;5:201-212. https://doi.org/10.1586/egh.11.6
  28. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007;46:582-589. https://doi.org/10.1002/hep.21768
  29. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009;50:1072-1078. https://doi.org/10.1002/hep.23050
  30. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006;44:27-33.
  31. Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 2002;16:663-678. https://doi.org/10.1053/bega.2002.0333
  32. Roskams T, Yang SQ, Koteish A, et al. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol 2003;163:1301-1311. https://doi.org/10.1016/S0002-9440(10)63489-X
  33. Gao D, Wei C, Chen L, Huang J, Yang S, Diehl AM. Oxidative DNA damage and DNA repair enzyme expression are inversely related in murine models of fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2004;287:G1070-1077. https://doi.org/10.1152/ajpgi.00228.2004
  34. Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004;99:1497-1502. https://doi.org/10.1111/j.1572-0241.2004.30159.x
  35. Abiru S, Migita K, Maeda Y, et al. Serum cytokine and soluble cytokine receptor levels in patients with nonalcoholic steatohepatitis. Liver Int 2006;26:39-45. https://doi.org/10.1111/j.1478-3231.2005.01191.x
  36. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008;103:1372-1379. https://doi.org/10.1111/j.1572-0241.2007.01774.x
  37. Kowdley KV, Belt P, Wilson LA, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012;55:77-85. https://doi.org/10.1002/hep.24706
  38. Neuschwander-Tetri BA, Clark JM, Bass NM, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010;52:913-924.
  39. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100. https://doi.org/10.1053/gast.2001.25540
  40. Poynard T, Ratziu V, Charlotte F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006;6:34. https://doi.org/10.1186/1471-230X-6-34
  41. Anty R, Iannelli A, Patouraux S, et al. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther 2010;32:1315-1322. https://doi.org/10.1111/j.1365-2036.2010.04480.x
  42. Younossi ZM, Page S, Rafiq N, et al. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg 2011;21:431-439. https://doi.org/10.1007/s11695-010-0204-1
  43. Alkhouri N, Berk M, Yerian L, et al. OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease. Dig Dis Sci 2014 Jan 25 [Epub]. http://dx.doi.org/10.1007/s10620-014-3031-8.
  44. Palekar NA, Naus R, Larson SP, Ward J, Harrison SA. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int 2006;26:151-156. https://doi.org/10.1111/j.1478-3231.2005.01209.x
  45. Tamimi TI, Elgouhari HM, Alkhouri N, et al. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol 2011;54:1224-1229. https://doi.org/10.1016/j.jhep.2010.08.023
  46. Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance? Hepatology 2010;51:373-375. https://doi.org/10.1002/hep.23521
  47. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-1362. https://doi.org/10.1002/hep.510300604
  48. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117-1123. https://doi.org/10.1016/S0016-5085(00)70364-7
  49. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010;59:1265-1269. https://doi.org/10.1136/gut.2010.216077
  50. Ipekci SH, Basaranoglu M, Sonsuz A. The fluctuation of serum levels of aminotransferase in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2003;36:371. https://doi.org/10.1097/00004836-200304000-00021
  51. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-1292. https://doi.org/10.1053/jhep.2003.50229
  52. Suzuki A, Lymp J, Sauver JS, Angulo P, Lindor K. Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. Liver Int 2006;26:1209-1216. https://doi.org/10.1111/j.1478-3231.2006.01362.x
  53. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57:1441-1447. https://doi.org/10.1136/gut.2007.146019
  54. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7:1104-1112. https://doi.org/10.1016/j.cgh.2009.05.033
  55. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection: comparison with liver biopsy and fibrotest. Hepatology 2007;46:32-36. https://doi.org/10.1002/hep.21669
  56. Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006;6:6. https://doi.org/10.1186/1471-230X-6-6
  57. Yu SJ, Kim D, Lee JH, et al. Validation of P2/MS and other noninvasive fibrosis scoring systems in the Korean population with nonalcoholic fatty liver disease. Korean J Gastroenterol 2011;57:19-27. https://doi.org/10.4166/kjg.2011.57.1.19
  58. Angulo P, Bugianesi E, Bjornsson ES, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013;145:782-789 e784. https://doi.org/10.1053/j.gastro.2013.06.057
  59. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008;47:455-460.
  60. Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010;59:1245-1251. https://doi.org/10.1136/gut.2009.203166
  61. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-854. https://doi.org/10.1002/hep.21496
  62. Cales P, Laine F, Boursier J, et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009;50:165-173.
  63. Ryan CK, Johnson LA, Germin BI, Marcos A. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl 2002;8:1114-1122. https://doi.org/10.1053/jlts.2002.36740
  64. Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol 2007;189:W320-323. https://doi.org/10.2214/AJR.07.2123
  65. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-750. https://doi.org/10.1053/gast.2002.35354
  66. Park SH, Kim PN, Kim KW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology 2006;239:105-112. https://doi.org/10.1148/radiol.2391050361
  67. Fishbein M, Castro F, Cheruku S, et al. Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol 2005;39:619-625. https://doi.org/10.1097/00004836-200508000-00012
  68. Thomas EL, Hamilton G, Patel N, et al. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 2005;54:122-127. https://doi.org/10.1136/gut.2003.036566
  69. Kim KM, Choi WB, Park SH, et al. Diagnosis of hepatic steatosis and fibrosis by transient elastography in asymptomatic healthy individuals: a prospective study of living related potential liver donors. J Gastroenterol 2007;42:382-388. https://doi.org/10.1007/s00535-007-2016-1
  70. Yoneda M, Yoneda M, Mawatari H, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008;40:371-378. https://doi.org/10.1016/j.dld.2007.10.019
  71. Nobili V, Vizzutti F, Arena U, et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008;48:442-448.
  72. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010;51:454-462. https://doi.org/10.1002/hep.23312
  73. Obara N, Ueno Y, Fukushima K, et al. Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases. J Gastroenterol 2008;43:720-728. https://doi.org/10.1007/s00535-008-2225-2
  74. Chang PE, Lui HF, Chau YP, et al. Prospective evaluation of transient elastography for the diagnosis of hepatic fibrosis in Asians: comparison with liver biopsy and aspartate transaminase platelet ratio index. Aliment Pharmacol Ther 2008;28:51-61. https://doi.org/10.1111/j.1365-2036.2008.03711.x
  75. Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE$^{TM}$ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010;36:1825-1835. https://doi.org/10.1016/j.ultrasmedbio.2010.07.005
  76. De Ledinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012;32:911-918. https://doi.org/10.1111/j.1478-3231.2012.02820.x
  77. Myers RP, Pollett A, Kirsch R, et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 2012;32:902-910. https://doi.org/10.1111/j.1478-3231.2012.02781.x
  78. Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011;259:749-756. https://doi.org/10.1148/radiol.11101942
  79. Kim D, Kim WR, Talwalkar JA, Kim HJ, Ehman RL. Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology 2013;268:411-419. https://doi.org/10.1148/radiol.13121193
  80. Adams LA, Angulo P. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis 2007;11:25-35. https://doi.org/10.1016/j.cld.2007.02.004
  81. Fassio E, Alvarez E, Domínguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004;40:820-826.
  82. Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989;111:473-478. https://doi.org/10.7326/0003-4819-111-6-473